Natera, Inc. (NASDAQ:NTRA) Shares Purchased by Comerica Bank

Comerica Bank boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 902.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,727 shares of the medical research company’s stock after buying an additional 102,385 shares during the period. Comerica Bank’s holdings in Natera were worth $18,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company’s stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock valued at $1,067,327,000 after purchasing an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock worth $1,060,836,000 after buying an additional 2,036,396 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Natera by 15.7% during the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company’s stock worth $512,898,000 after buying an additional 439,778 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Natera by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company’s stock valued at $355,809,000 after buying an additional 142,201 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on NTRA. Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Barclays reduced their price objective on Natera from $200.00 to $160.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Guggenheim lifted their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Robert W. Baird increased their price target on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $175.76.

Natera Stock Performance

Shares of NTRA stock opened at $151.36 on Friday. The company has a market capitalization of $20.46 billion, a P/E ratio of -86.00 and a beta of 1.80. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00. The business’s 50 day moving average is $146.92 and its two-hundred day moving average is $153.99. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 6,203 shares of the business’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $152.18, for a total transaction of $943,972.54. Following the transaction, the chief executive officer now directly owns 192,162 shares in the company, valued at approximately $29,243,213.16. The trade was a 3.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 2,018 shares of the business’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $152.18, for a total value of $307,099.24. Following the transaction, the chief financial officer now owns 73,539 shares in the company, valued at approximately $11,191,165.02. This represents a 2.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 182,621 shares of company stock valued at $27,727,077 over the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.